Table of Contents
ISRN Dermatology
Volume 2012, Article ID 405268, 8 pages
http://dx.doi.org/10.5402/2012/405268
Review Article

The Newest Hypothesis about Vitiligo: Most of the Suggested Pathogeneses of Vitiligo Can Be Attributed to Lack of One Factor, Zinc-α2-Glycoprotein

Nooshin Bagherani's Office, 2nd Floor, Taha Physicians' Building, 40-Meter Street, Khoramshahr, Khuzestan Province, Iran

Received 15 March 2012; Accepted 18 April 2012

Academic Editors: E. Alpsoy, H. Takahashi, and A. Zalewska

Copyright © 2012 Nooshin Bagherani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Mracek, N. A. Stephens, D. Gao et al., “Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients,” British Journal of Cancer, vol. 104, no. 3, pp. 441–447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Mracek, Q. Ding, T. Tzanavari et al., “The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity,” Clinical Endocrinology, vol. 72, no. 3, pp. 334–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Tzanavari, C. Bing, and P. Trayhurn, “Postnatal expression of zinc-α2-glycoprotein in rat white and brown adipose tissue,” Molecular and Cellular Endocrinology, vol. 279, no. 1-2, pp. 26–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Bao, C. Bing, L. Hunter, J. R. Jenkins, M. Wabitsch, and P. Trayhurn, “Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes,” FEBS Letters, vol. 579, no. 1, pp. 41–47, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. L. P. Hale, D. T. Price, L. M. Sanchez, W. Demark-Wahnefried, and J. F. Madden, “Zinc α-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer,” Clinical Cancer Research, vol. 7, no. 4, pp. 846–853, 2001. View at Google Scholar · View at Scopus
  6. A. Descazeaud, A. de la Taille, Y. Allory et al., “Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system,” Prostate, vol. 66, no. 10, pp. 1037–1043, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. I. Hassan, A. Waheed, S. Yadav, T. P. Singh, and F. Ahmad, “Zinc α2-glycoprotein: a multidisciplinary protein,” Molecular Cancer Research, vol. 6, no. 6, pp. 892–906, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Yaghoobi, M. Omidian, and N. Bagherani, “Vitiligo: a review of the published work,” Journal of Dermatology, vol. 38, no. 5, pp. 419–431, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. L. P. Hale, “Zinc α-2-glycoprotein regulates melanin production by normal and malignant melanocytes,” Journal of Investigative Dermatology, vol. 119, no. 2, pp. 464–470, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Burgi and K. Schmid, “Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma,” The Journal of Biological Chemistry, vol. 236, pp. 1061–1074, 1961. View at Google Scholar · View at Scopus
  11. T. Araki, F. Gejyo, K. Takagaki et al., “Complete amino acid sequence of human plasma Zn-α2-glycoprotein and its homology to histocompatibility antigens,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 3, pp. 679–683, 1988. View at Google Scholar · View at Scopus
  12. L. C. McDermott, J. A. Freel, A. P. West, P. J. Bjorkman, and M. W. Kennedy, “Zn-α2-glycoprotein, an MHC class I-related glycoprotein regulator of adipose tissues: modification or abrogation of ligand binding by site-directed mutagenesis,” Biochemistry, vol. 45, no. 7, pp. 2035–2041, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. K. Guo, H. Chen, B. Zhang et al., “Polymorphisms of ZAG gene with growth traits in Jiaxian red cattle,” Yi Chuan, vol. 30, no. 11, pp. 1417–1420, 2008. View at Google Scholar · View at Scopus
  14. C. Huang, N. Na, L. Huang, D. He, and J. Ouyang, “TEMED enhanced photoluminescent imaging detection of proteins in human serum using quantum dots after PAGE,” Journal of Proteome Research, vol. 9, no. 11, pp. 5574–5581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. M. Sánchez, A. J. Chirino, and P. Bjorkman, “Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules,” Science, vol. 283, no. 5409, pp. 1914–1919, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Schmitt, A. Marlier, and L. G. Cantley, “Zag expression during aging suppresses proliferation after kidney injury,” Journal of the American Society of Nephrology, vol. 19, no. 12, pp. 2375–2383, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Mracek, D. Gao, T. Tzanavari et al., “Downregulation of zinc-α2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-α in adipocytes,” Journal of Endocrinology, vol. 204, no. 2, pp. 165–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Rolli, M. Radosavljevic, V. Astier et al., “Lipolysis is altered in MHC class I zinc-α2-glycoprotein deficient mice,” FEBS Letters, vol. 581, no. 3, pp. 394–400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Philipp, S. Kralisch, A. Bachmann et al., “Serum levels of the adipokine zinc-α2-glycoprotein are increased in chronic hemodialysis,” Metabolism, vol. 60, no. 5, pp. 669–672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. T. Russell and M. J. Tisdale, “The role of glucocorticoids in the induction of zinc-α2-glycoprotein expression in adipose tissue in cancer cachexia,” British Journal of Cancer, vol. 92, no. 5, pp. 876–881, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. T. Russell, T. P. Zimmerman, B. A. Domin, and M. J. Tisdale, “Induction of lipolysis in vitro and loss of body fat in vivo by zinc-α2-glycoprotein,” Biochimica et Biophysica Acta, vol. 1636, no. 1, pp. 59–68, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Bing, Y. Bao, J. Jenkins et al., “Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2500–2505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. T. Russell and M. J. Tisdale, “Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 72, no. 6, pp. 409–414, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Brysk, G. Lei, P. Selvanayagam, H. Brysk, S. K. Tyring, and I. Arany, “Modulation by interferon-γ of zinc-α2-glycoprotein gene expression in human epithelial cell lines,” Anticancer Research, vol. 17, no. 5A, pp. 3387–3392, 1997. View at Google Scholar · View at Scopus
  25. D. Gao, P. Trayhurn, and C. Bing, “Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes,” Molecular and Cellular Endocrinology, vol. 325, no. 1-2, pp. 135–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. M. Sanders and M. J. Tisdale, “Effect of zinc-α2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue,” Cancer Letters, vol. 212, no. 1, pp. 71–81, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Bing, T. Mracek, D. Gao, and P. Trayhurn, “Zinc-α2-glycoprotein: an adipokine modulator of body fat mass,” International Journal of Obesity, vol. 34, no. 11, pp. 1559–1565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Y. Gong, S. J. Zhang, J. Y. Deng et al., “Zinc-α2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue,” International Journal of Obesity, vol. 33, no. 9, pp. 1023–1030, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Y. Gong, J. Y. Deng, H. J. Zhu, H. Pan, L. J. Wang, and H. B. Yang, “Fatty acid synthase and hormone-sensitive lipase expression in liver are involved in zinc-α2-glycoprotein-induced body fat loss in obese mice,” Chinese Medical Sciences Journal, vol. 25, no. 3, pp. 169–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. P. Marrades, J. A. Martínez, and M. J. Moreno-Aliaga, “ZAG, a lipid mobilizing adipokine, is downregulated in human obesity,” Journal of Physiology and Biochemistry, vol. 64, no. 1, pp. 61–66, 2008. View at Google Scholar · View at Scopus
  31. S. T. Russell and M. J. Tisdale, “Studies on the antiobesity effect of zinc-α 2-glycoprotein in the ob/ob mouse,” International Journal of Obesity, vol. 35, no. 3, pp. 345–354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. P. T. Todorov, T. M. McDevitt, D. J. Meyer, H. Ueyama, I. Ohkubo, and M. J. Tisdale, “Purification and characterization of a tumor lipid-mobilizing factor,” Cancer Research, vol. 58, no. 11, pp. 2353–2358, 1998. View at Google Scholar · View at Scopus
  33. M. L. Knapp, S. Al-Sheibani, P. G. Riches, I. W. F. Hanham, and R. H. Phillips, “Hormonal factors associated with weight loss in patients with advanced breast cancer,” Annals of Clinical Biochemistry, vol. 28, no. 5, pp. 480–486, 1991. View at Google Scholar · View at Scopus
  34. K. Eckardt, A. Schober, B. Platzbecker et al., “The adipokine zinc-α2-glycoprotein activates AMP kinase in human primary skeletal muscle cells,” Archives of Physiology and Biochemistry, vol. 117, no. 2, pp. 88–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. T. Russell and M. J. Tisdale, “Studies on the anti-obesity activity of zinc-α 2-glycoprotein in the rat,” International Journal of Obesity, vol. 35, no. 5, pp. 658–665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. T. Russell and M. J. Tisdale, “Mechanism of attenuation of skeletal muscle atrophy by zinc-α2-glycoprotein,” Endocrinology, vol. 151, no. 10, pp. 4696–4704, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. L. E. Olofsson, B. Olsson, T. Lystig et al., “Preliminary report: Zn-alpha2-glycoprotein genotype and serum levels are associated with serum lipids,” Metabolism, vol. 59, no. 9, pp. 1316–1318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Stejskal, M. Karpíšek, H. Reutová, P. Stejskal, H. Kotolová, and P. Kollár, “Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA,” Clinical Biochemistry, vol. 41, no. 4-5, pp. 313–316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Reichel, “Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS,” Journal of Mass Spectrometry, vol. 43, no. 7, pp. 916–923, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Frenette, M. Thabet, and R. Sullivan, “Polyol pathway in human epididymis and semen,” Journal of Andrology, vol. 27, no. 2, pp. 233–239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Ding, F. Qu, W. Guo, X. Ying, M. Wu, and Y. Zhang, “Identification of sperm forward motility-related proteins in human seminal plasma,” Molecular Reproduction and Development, vol. 74, no. 9, pp. 1124–1131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Lei, I. Arany, P. Selvanayagam, S. Rajaraman, S. Ram, and H. Brysk, “Detection and cloning of epidermal zinc-α2-glycoprotein cDNA and expression in normal human skin and in tumors,” Journal of Cellular Biochemistry, vol. 67, pp. 216–222, 1997. View at Google Scholar
  43. P. R. Gordon and B. A. Gilchrest, “Human melanogenesis is stimulated by diacylglycerol,” Journal of Investigative Dermatology, vol. 93, no. 5, pp. 700–702, 1989. View at Google Scholar · View at Scopus
  44. P. R. Gordon, C. P. Mansur, and B. A. Gilchrest, “Regulation of human melanocyte growth, dendricity and melanization by keratinocyte derived factors,” Journal of Investigative Dermatology, vol. 92, no. 4, pp. 565–572, 1989. View at Google Scholar · View at Scopus
  45. M. Matsumura, D. H. Fremont, P. A. Peterson, and I. A. Wilson, “Emerging principles for the recognition of peptide antigens by MHC class I molecules,” Science, vol. 257, no. 5072, pp. 927–934, 1992. View at Google Scholar · View at Scopus
  46. D. M. Hill, T. Kasliwal, E. Schwarz et al., “A dominant negative mutant β2-microglobulin blocks the extracellular folding of a major histocompatibility complex class I heavy chain,” Journal of Biological Chemistry, vol. 278, no. 8, pp. 5630–5638, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Lie, H. Brysk, I. Arany et al., “Characterization of Zinc-α(2)-glycoprotein as a cell adhesion molecule that inhibits the proliferation of an oral tumor cell line,” Journal of Cellular Biochemistry, vol. 75, pp. 160–169, 1999. View at Google Scholar
  48. G. Lei, I. Arany, S. K. Tyring, H. Brysk, and M. M. Brysk, “Zinc-α2-glycoprotein has ribonuclease activity,” Archives of Biochemistry and Biophysics, vol. 355, no. 2, pp. 160–164, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. E. V. Koonin and M. P. Deutscher, “RNase T shares conserved sequence motifs with DNA proofreading exonucleases,” Nucleic Acids Research, vol. 21, no. 10, pp. 2521–2522, 1993. View at Google Scholar · View at Scopus
  50. G. O'Hurley, A. O'Grady, P. Smyth et al., “Evaluation of Zinc-α-2-glycoprotein and proteasome subunit β-type 6 expression in prostate cancer using tissue microarray technology,” Applied Immunohistochemistry and Molecular Morphology, vol. 18, no. 6, pp. 512–517, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Irmak, D. Tilki, J. Heukeshoven et al., “Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer,” Proteomics, vol. 5, no. 16, pp. 4296–4304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Lapointe, C. Li, J. P. Higgins et al., “Gene expression profiling identifies clinically relevant subtypes of prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 3, pp. 811–816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Bing and P. Trayhurn, “New insights into adipose tissue atrophy in cancer cachexia,” Proceedings of the Nutrition Society, vol. 68, no. 4, pp. 385–392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M. García-Ramírez, F. Canals, C. Hernández et al., “Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy,” Diabetologia, vol. 50, no. 6, pp. 1294–1303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. X. Jia, C. Gan, K. Xiao et al., “Detection of urinary biomarkers for early diagnosis of acute renal allograft rejection by proteomic analysis,” Proteomics, vol. 3, no. 6, pp. 694–704, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Rajpal, P. Dowling, J. Meiller et al., “A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients,” Proteomics, vol. 11, no. 8, pp. 1391–1402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Tumani, V. Lehmensiek, D. Rau et al., “CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis,” Neuroscience Letters, vol. 452, no. 2, pp. 214–217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Yilmaz, O. Yonal, F. Eren et al., “Serum zinc-α2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 1, pp. 93–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. M. I. Helmy, E. I. M. A. Gayyar, S. Hawas, and E. A. Eissa, “Role of oxidative stress in the pathogenesis of vitiligo,” Journal of Pan Arab League of Dermatologists, vol. 15, pp. 97–105, 2004. View at Google Scholar
  60. P. Shameer, P. V. S. Prasad, and P. K. Kaviarasan, “Serum zinc level in vitiligo: a case control study,” Indian Journal of Dermatology, Venereology and Leprology, vol. 71, no. 3, pp. 206–207, 2005. View at Google Scholar · View at Scopus
  61. R. Yaghoobi, M. Omidian, and N. Bagherani, “Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial,” BMC Dermatology, vol. 11, article 7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Wolff, L. A. Goldsmith, B. A. Gilchrest, A. S. Paller, and D. J. Leffell, Fitzpatrick's Dermatology in General Medicine, Mac Graw Hill, 7 edition, 2007.
  63. M. S. Birbeck, A. S. Breathnach, and J. D. Everall, “An electron microscope study of basal melanocytes and high level-clear cells(Langerhans cells) in vitiligo,” Journal of Investigative Dermatology, vol. 37, pp. 51–54, 1961. View at Google Scholar
  64. N. Bagherani, R. Yaghoobi, and M. Omidian, “Hypothesis: zinc can be effective in treatment of vitiligo. Indian,” The Journal of Dermatology, vol. 56, pp. 497–501, 2011. View at Google Scholar
  65. Y. Jin, S. L. Riccardi, K. Gowan, P. R. Fain, and R. A. Spritz, “Fine-mapping of vitiligo susceptibility loci on chromosomes 7 and 9 and interactions with NLRP1 (NALP1),” Journal of Investigative Dermatology, vol. 130, no. 3, pp. 774–783, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. I. C. Le Poole, P. K. Das, R. M. J. G. J. van den Wijngaard, J. D. Bos, and W. Westerhof, “Review of the etiopathomechanism of vitiligo: a convergence theory,” Experimental Dermatology, vol. 2, no. 4, pp. 145–153, 1993. View at Publisher · View at Google Scholar · View at Scopus
  67. R. E. Boissy and R. A. Spritz, “Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff,” Experimental Dermatology, vol. 18, no. 7, pp. 583–585, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. R. L. Mandelcorn-Monson, N. H. Shear, E. Yau et al., “Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients,” Journal of Investigative Dermatology, vol. 121, no. 3, pp. 550–556, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Moretti, A. Spallanzani, L. Amato et al., “New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions,” Pigment Cell Research, vol. 15, no. 2, pp. 87–92, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Manolache and V. Benea, “Stress in patients with alopecia areata and vitiligo,” Journal of the European Academy of Dermatology and Venereology, vol. 21, no. 7, pp. 921–928, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Gauthier, M. Cario-Andre, S. Lepreux, C. Pain, and A. Taïeb, “Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo,” British Journal of Dermatology, vol. 148, no. 1, pp. 95–101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Gauthier, M. Cario-Andre, and A. Taïeb, “A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?” Pigment Cell Research, vol. 16, no. 4, pp. 322–332, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Torello, G. Alessia, F. Zanieri, R. Colucci, and S. Moretti, “Vitiligo: new and emerging treatments,” Dermatologic Therapy, vol. 21, no. 2, pp. 110–117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Castanet and J. P. Ortonne, “Pathophysiology of vitiligo,” Clinics in Dermatology, vol. 15, no. 6, pp. 845–851, 1997. View at Publisher · View at Google Scholar · View at Scopus
  75. M. G. Lebwohl, W. R. Heymann, J. Berth-Jones, and I. Coulson, Treatment of Skin Disease: Comprehensive Therapeutic Strategies, Mosby Elsevier, 2nd edition, 2006.
  76. T. Burns, S. Breathnach, N. Cox, and C. Griffiths, Rook's Textbook of Dermatology, vol. 2, Oxford Blackwell Science, 7th edition, 2004.
  77. M. E. Whitton, D. M. Ashcroft, and U. González, “Therapeutic interventions for vitiligo,” Journal of the American Academy of Dermatology, vol. 59, no. 4, pp. 713–717, 2008. View at Publisher · View at Google Scholar · View at Scopus